NovaBay Pharmaceuticals is a biopharmaceutical company focused on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, which was initially cleared by the FDA; CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™. For more information, visit the company’s website at www.novabay.com